Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4901 · 1 trial · 1 indication
Change-from-baseline of luteinising hormone area under the concentration-time curve from time zero to 8 hours postdose \[AUC(0-8)\] at Day 7
| Arm | Type | Description |
|---|---|---|
| AZD4901 20 mg once a day | EXPERIMENTAL | AZD4901 20 mg once a day |
| AZD4901 20mg twice a day | EXPERIMENTAL | AZD4901 20mg twice a day |
| AZD4901 40 mg twice a day | EXPERIMENTAL | AZD4901 40 mg twice a day |
| Placebo to match AZD4901 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AZD4901 (oral) | DRUG | Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo |
| Placebo to match AZD4901 | DRUG | Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo |
Inclusion Criteria: Female patients between the ages of 18 to 45 years (inclusive). Suitable veins for cannulation or repeated venipuncture. Body mass index (BMI) between 18 and 40 kg/m2 (inclusive). A diagnosis of polycystic ovary disease. Amenorrhea or oligomenorrhea (defined as ≤ 6 menses per ye...
AZD4901 is an investigational small molecule being studied for the treatment of Polycystic Ovary Syndrome (PCOS) and Female Endocrine Disorder. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
AZD4901 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 2 clinical trials for endocrine conditions.
AZD4901 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies and is still being evaluated in clinical trials for safety and efficacy.
AZD4901 has one completed Phase 2 clinical trial, identified as NCT01872078, which studied the drug in females with Polycystic Ovary Syndrome. The trial enrolled 67 participants across the United States, Germany, and the United Kingdom.
No alternative names for AZD4901 have been disclosed in the available information. The drug is referred to solely by its development code AZD4901 in clinical trial records and related documentation.